Quick Answer
Axsome Therapeutics, Inc. reported Total Revenue of $638.50 million for fiscal year 2025.
Axsome Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $638.50M +65.5% |
$385.69M +42.5% |
$270.60M +440.8% |
$50.04M | — | — |
| Revenue (ASC 606) | $638.50M +65.5% |
$385.69M +42.5% |
$270.60M +440.8% |
$50.04M | — | — |
| Net Income | -$183.17M +36.2% |
-$287.22M -20.1% |
-$239.24M -27.8% |
-$187.13M -43.5% |
-$130.40M -26.7% |
-$102.90M -50.6% |
| Diluted EPS | -$3.68 +38.6% |
-$5.99 -13.7% |
-$5.27 -14.6% |
-$4.60 -32.6% |
-$3.47 -25.3% |
-$2.77 |
| Total Assets | $689.80M +21.3% |
$568.50M -3.4% |
$588.24M +77.5% |
$331.48M +277.6% |
$87.79M -52.8% |
$186.13M -15.6% |
| Cash and Equivalents | $322.93M +2.4% |
$315.35M -18.3% |
$386.19M +92.3% |
$200.84M +132.3% |
$86.47M -53.0% |
$183.88M -16.4% |
| Long-Term Debt | $117.75M -34.8% |
$180.71M +1.5% |
$178.07M +88.9% |
$94.26M +92.0% |
$49.09M +1.6% |
$48.32M +178.8% |
| Stockholders Equity | $88.30M +54.9% |
$57.02M -70.1% |
$190.98M +74.3% |
$109.56M +600.9% |
$15.63M -86.3% |
$113.79M -36.3% |
| R&D Expense | $183.28M -2.0% |
$187.08M +91.0% |
$97.94M +69.0% |
$57.95M -0.2% |
$58.06M -17.3% |
$70.24M +30.9% |
| Operating Income | -$166.76M +40.6% |
-$280.56M -21.0% |
-$231.82M -28.9% |
-$179.80M -44.2% |
-$124.71M -25.8% |
-$99.14M -47.4% |
| Shares Outstanding | 50.88M +4.6% |
48.67M +2.8% |
47.35M +8.9% |
43.50M +15.0% |
37.82M +1.2% |
37.37M +1.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $170.99M | +63.2% | +14.0% |
| Revenue (ASC 606) | September 30, 2025 | $170.99M | +63.2% | +14.0% |
| Net Income | September 30, 2025 | -$47.23M | +26.9% | +1.6% |
| Diluted EPS | September 30, 2025 | -$0.94 | +29.9% | +3.1% |
| Total Assets | September 30, 2025 | $669.25M | +19.2% | +4.6% |
| Cash and Equivalents | September 30, 2025 | $325.27M | -0.6% | +7.3% |
| Long-Term Debt | September 30, 2025 | $117.64M | -34.6% | +0.1% |
| Stockholders Equity | September 30, 2025 | $73.73M | -20.6% | +0.9% |
| R&D Expense | September 30, 2025 | $40.16M | -11.5% | -18.9% |
| Operating Income | September 30, 2025 | -$46.11M | +26.4% | -25.6% |
| Shares Outstanding | September 30, 2025 | 50.31M | +3.9% | +1.0% |
- Axsome Therapeutics, Inc. reported Total Revenue of $638.50 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +65.5% in Total Revenue compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Revenue (ASC 606) of $638.50 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +65.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Net Income of -$183.17 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +36.2% in Net Income compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Diluted EPS of $3.68 per share (loss) for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +38.6% in Diluted EPS compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Total Assets of $689.80 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +21.3% in Total Assets compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Cash and Equivalents of $322.93 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +2.4% in Cash and Equivalents compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Long-Term Debt of $117.75 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed a decrease of -34.8% in Long-Term Debt compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Stockholders Equity of $88.30 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +54.9% in Stockholders Equity compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported R&D Expense of $183.28 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed a decrease of -2.0% in R&D Expense compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Operating Income of -$166.76 million for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +40.6% in Operating Income compared to the prior fiscal year.
- Axsome Therapeutics, Inc. reported Shares Outstanding of 50.88 million shares for fiscal year 2025.
- Axsome Therapeutics, Inc. showed an increase of +4.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: